PYC 5.26% 10.0¢ pyc therapeutics limited

Safety approval VP-001, page-3

  1. 627 Posts.
    lightbulb Created with Sketch. 50
    Next cohort (#2) is medium dose, followed by #3 cohort which will be high dose.

    In PYC's June '23 Investor Update presentation, page 14, provides some interesting info on patient derived models, (patient organoids), which points towards safety and efficacy in a good way. PYC also makes reference to wishing to know likely outcomes before expensive clinical trials get underway.

    For me personally, I like PYC's approach, they seem to have their ducks lined up very strategically and whilst nothing is completely free of risk, I feel they are progressively ticking the right boxes as they move forward and have taken as much risk off the table as they can for the stage they are at.

    https://hotcopper.com.au/threads/ann-pyc-investor-update-presentation.7432807/
 
watchlist Created with Sketch. Add PYC (ASX) to my watchlist
(20min delay)
Last
10.0¢
Change
0.005(5.26%)
Mkt cap ! $466.6M
Open High Low Value Volume
10.0¢ 10.0¢ 9.7¢ $126.7K 1.277M

Buyers (Bids)

No. Vol. Price($)
2 10306 9.8¢
 

Sellers (Offers)

Price($) Vol. No.
10.0¢ 91480 2
View Market Depth
Last trade - 16.10pm 14/05/2024 (20 minute delay) ?
Last
9.9¢
  Change
0.005 ( 4.21 %)
Open High Low Volume
10.0¢ 10.0¢ 9.7¢ 96942
Last updated 15.25pm 14/05/2024 ?
PYC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.